46P - Platelet-derived growth factor associated protein-1: A plausible function in Gliomas

Date 20 November 2015
Event ESMO Symposium on Immuno-Oncology 2015
Session Welcome reception and general Poster viewing
Topics Cancer biology
Central Nervous System Malignancies
Basic Scientific Principles
Presenter Savita Yadav
Citation Annals of Oncology (2015) 26 (suppl_8): 5-14. 10.1093/annonc/mdv514
Authors S. Yadav1, V.K. Sharma1, A. Singh2, S.K. Srivastava3, V. Kumar4, A. Nalwa3, A.K. Dinda3, P. Chattopadhyay2
  • 1Biophysics, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 2Biochemistry, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 3Pathology, All India Institute of Medical Sciences, New Delhi/IN
  • 4Igib, Institute of genomics and Integrative Biology, 110025 - New Delhi/IN

Abstract

Aim

The aim of this study was to investigate the role of PDAP-1 in PDGF signaling and its effect on PDGF downstream genes/proteins followed by the development of a novel combinatorial approach for the treatment of human malignant gliomas.

Methods

we studied the expression of PDAP-1 in grade III and grade IV glioma cell lines as well as in tissue samples followed by its knockdown in two GBM cell lines (U87MG and U373) with high PDAP-1 expression. We characterize the molecular alterations of PDGF signaling caused by PDAP-1 knockdown in glioma cells using various techniques. Interaction between PDAP-1 and PDGF was also established with different biophysical methods.

Results

We observed that the expression of PDAP-1 increases with the degree of malignancy and it is able to regulate the expression of PDGF-B and its downstream genes/proteins in human gliomas. It was also revealed that both PDAP-1 and PDGF-B are interacting partners which co-localize in the cytoplasm of glioma cells.

Conclusions

So far, there have been no studies showing the direct effect of PDAP-1 on PDGF signaling. Our results suggest that PDAP-1 may regulate the activity of PDGF and it can be used as a therapeutic target for the treatment of human gliomas.

Clinical trial identification

Disclosure

All authors have declared no conflicts of interest.